IgG in cervicovaginal mucus traps HSV and prevents vaginal Herpes infections

Wang, Y-Y; Kannan, A; Nunn, K L; Murphy, M A; Subramani, D B; Moench, T; Cone, R; Lai, S K
September 2014
Mucosal Immunology (1933-0219);Sep2014, Vol. 7 Issue 5, p1036
Academic Journal
IgG is the predominant immunoglobulin in cervicovaginal mucus (CVM), yet how immunoglobulin G (IgG) in mucus can protect against infections is not fully understood. IgG diffuses rapidly through cervical mucus, slowed only slightly by transient adhesive interactions with mucins. We hypothesize that this almost unhindered diffusion allows IgG to accumulate rapidly on pathogen surfaces, and the resulting IgG array forms multiple weak adhesive crosslinks to mucus gel that effectively trap (immobilize) pathogens, preventing them from initiating infections. Here, we report that herpes simplex virus serotype 1 (HSV-1) readily penetrated fresh, pH-neutralized ex vivo samples of CVM with low or no detectable levels of anti-HSV-1 IgG but was trapped in samples with even modest levels of anti-HSV-1 IgG. In samples with little or no endogenous anti-HSV-1 IgG, addition of exogenous anti-HSV-1 IgG, affinity-purified from intravenous immunoglobulin, trapped virions at concentrations below those needed for neutralization and with similar potency as endogenous IgG. Deglycosylating purified anti-HSV-1 IgG, or removing its Fc component, markedly reduced trapping potency. Finally, a non-neutralizing IgG against HSV-gG significantly protected mice against vaginal infection, and removing vaginal mucus by gentle lavage abolished protection. These observations suggest that IgG-Fc has a glycan-dependent 'muco-trapping' effector function that may provide exceptionally potent protection at mucosal surfaces.


Related Articles

  • Susceptibility of Herpes Simplex Virus Isolates to Nucleoside Analogues and the Proportion of Nucleoside-Resistant Variants after Repeated Topical Application of Penciclovir to Recurrent Herpes Labialis. Young Kyoo Shin; Weinberg, Adriana; Spruance, Spotswood; Bernard, Mariann; Bacon, Teresa H.; Boon, Ron J.; Levin, Myron J. // Journal of Infectious Diseases;4/15/2003, Vol. 187 Issue 8, p1241 

    Reports on a study in which subjects received topical penciclovir for four days during successive episodes of recurrent herpes labialis. Isolation of herpes simplex virus from lesions; Proportion of nucleoside-resistant variants present within a subset of these isolates; Inability of...

  • Towards an Understanding of the Herpes Simplex Virus Type 1 Latency-Reactivation Cycle. Guey-Chuen Perng; Jones, Clinton // Interdisciplinary Perspectives on Infectious Diseases;2010, p1 

    Infection by herpes simplex virus type 1 (HSV-1) can cause clinical symptoms in the peripheral and central nervous system. Recurrent ocular shedding can lead to corneal scarring and vision loss making HSV-1 a leading cause of corneal blindness due to an infectious agent. The primary site of...

  • Prevention of Genital Herpes Simplex Virus Type 1 and 2 Disease in Mice Immunized with a gD-Expressing Dominant-Negative Recombinant HSV-1. Brans, Richard; Akhrameyeva, Natali V.; Feng Yao // Journal of Investigative Dermatology;Oct2009, Vol. 129 Issue 10, p2470 

    CJ9-gD is a novel herpes simplex virus (HSV) type 1 recombinant virus that is completely replication-defective, expresses high-levels of HSV-1 major antigen glycoprotein D (gD), and can function in trans to inhibit replication of wild-type HSV-1 and HSV-2 in co-infected cells. Here, we show that...

  • Revisi�n de tratamientos naturales en infecciones por el HERPES. Pablo, Saz Peir�; Shila, Saz Tejero // Medicina Naturista;ene-jun2012, Vol. 6 Issue 1, p30 

    Simple hygienic care and natural treatment based on medicinal plants have proven to be effective in the prevention and treatment of herpes in its various forms.

  • A Risk-Benefit Evaluation of Aciclovir for the Treatment and Prophylaxis of Herpes Simplex Virus Infections. Leflore, S.; Anderson, P.L.; Fletcher, C.V. // Drug Safety;Aug2000, Vol. 23 Issue 2, p131 

    The objective of this article is to review and evaluate risks and benefits associated with the use of aciclovir in the treatment and prophylaxis of common manifestations of herpes simplex virus (HSV) infections in immunocompetent and immunocompromised patients. Information was found through a...

  • Cure for Cold Sores?  // Time;7/12/1971, Vol. 98 Issue 2, p53 

    The article informs that dermatologists at the Baylor University College of Medicine in Houston, Texas have developed a treatment for curing cold sores. It informs that sores are produced by the herpes simplex virus. It tells that sores generally appear on the lips, around the eyes and on the...

  • Recurrent herpes simplex labialis: selected therapeutic options. Raborn, G. Wayne; Grace, Michael G. A. // Journal of the Canadian Dental Association;Sep2003, Vol. 69 Issue 8, p498 

    Recurrent infection with herpes simplex virus 1 (HSV1), called herpes simplex labialis (HSL), is a global problem for patients with normal immune systems. An effective management program is needed for those with frequent HSL recurrences, particularly if associated morbidity and life-threatening...

  • In vitro inhibitory effects of chlorhexidine and Persica mouthwashes on HSV-1 compared with acyclovir. Poorshahidi, Sara; Davarmanesh, Mehdi; Rezazadeh, Fahimeh; Motamedifar, Mohammad; Ebrahimi, Hooman; Alipour, Abbas // Journal of Isfahan Dental School;Mar2011, Special section p1 

    Introduction: Recurrent intraoral herpes is a common oral disease that causes painful ulcers and viral shedding, resulting in various complications for patients. The antiviral efficacy of oral mouthwashes has not been adequately studied, although they are a readily available and rapid treatment...

  • Experimental study on antiviral activity of silicone oil in vitro. Hua Yan; Jun Li // Graefe's Archive of Clinical & Experimental Ophthalmology;Sep2008, Vol. 246 Issue 9, p1285 

    Abstract Objective  To study the antiviral activity of silicone oil against herpes simplex virus-1 (HSV-1) in vitro. Methods  (1) TCID50 (Tissue culture infectious dose 50% endpoint) of HSV-1 was titrated. (2) The Hela cells were placed in a 96-well plate. (3) The virus was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics